Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

被引：17

作者：

Langrand-Escure, J. ^{[1
]}

de Crevoisier, R. ^{[2
,3
]}

Llagostera, C. ^{[4
]}

Crehange, G. ^{[5
]}

Delaroche, G. ^{[1
]}

Lafond, C. ^{[2
,3
]}

Bonin, C. ^{[6
]}

Bideault, F. ^{[5
]}

Sargos, P. ^{[7
]}

Belhomme, S. ^{[7
]}

Pasquier, D. ^{[8
]}

Latorzeff, I ^{[9
]}

Supiot, S. ^{[4
]}

Hennequin, C. ^{[10
]}

机构：

[1] Inst Cancerol La Loire Lucien Neuwirth, 180 Bis,Ave Albert Raimond, F-42270 St Priest En Jarez, France

[2] Ctr Eugene Marquis, Dept Radiotherapie, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France

[3] Inserm 1099, LTSI, 263 Ave Gen Leclerc, F-35042 Rennes, France

[4] Inst cancerol Ouest Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France

[5] Ctr Georges Francois Leclerc, Dept Radiotherapie, 1 Ave Prof Marion, F-21000 Dijon, France

[6] CHU Jean Minjoz, Serv Radiotherapie, 3 Blvd Alexandre Fleming, F-25000 Besancon, France

[7] Inst Bergonie, Dept Radiotherapie, 229 Cours Argonne, F-33000 Bordeaux, France

[8] Ctr Oscar Lambret, Dept Radiotherapie, 3 Rue Frederic Combemale, F-59020 Lille, France

[9] Clin Pasteur, Dept Oncol Radiotherapie, Bat Atrium,1 Rue Petite Vitesse, F-31300 Toulouse, France

[10] Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France

来源：

CANCER RADIOTHERAPIE | 2018年 / 22卷 / 02期

关键词：

Prostate cancer; Hypofractionation; Radiotherapy; Image-guided radiation therapy; Recommendations; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; RADIATION-THERAPY; NON-INFERIORITY; PHASE-3; TRIAL; ACUTE TOXICITY; HIGH-RISK; ADENOCARCINOMA;

D O I：

10.1016/j.canrad.2017.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).

引用

页码：193 / 198

页数：6

共 50 条

[41] Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes
Faria, Sergio L.
Neto, Osmar B.
Cury, Fabio
Shenouda, George
Russel, Ruo
Souhami, Luis
CANADIAN JOURNAL OF UROLOGY, 2016, 23 (02) : 8209 - 8214
[42] Identification of the bladder dose and volume constraints to control late urinary toxicity after external beam radiotherapy for prostate cancer
Cheung, R.
Tucker, S.
de Crevoisier, R.
Lee, A.
Frank, S.
Kudchadker, R.
Thames, H.
Mohan, R.
Kuban, D.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S37 - S38
[43] Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis
Cao, Ling
Yang, Yong-Jing
Li, Zhi-Wen
Wu, Hong-Fen
Yang, Zhu-Chun
Liu, Shi-Xin
Wang, Ping
ONCOTARGET, 2017, 8 (02) : 2647 - 2658
[44] EVALUATION OF PLANNING TARGET VOLUME (PTV) IN THE OUTCOMES OF PROSTATE CANCER PATIENTS TREATED WITH MODERATE HYPOFRACTIONATED RADIOTHERAPY
Soliman, Rania
Souhami, Luis
Duclos, Marie
Cury, Fabio
Patrocinio, Horacio
Faria, Sergio
RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S54 - S54
[45] Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
Lazo, Antonio
de la Torre-Luque, Alejandro
Arregui, Gregorio
Rivas, Daniel
Serradilla, Ana
Gomez, Joaquin
Jurado, Francisca
Isabel Nunez, Maria
Lopez, Escarlata
BIOLOGY-BASEL, 2022, 11 (03):
[46] Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
Kountouri, Melpomeni
Zilli, Thomas
Rouzaud, Michel
Dubouloz, Angele
Linero, Dolors
Escude, Lluis
Jorcano, Sandra
Miralbell, Raymond
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (02): : 272 - 279
[47] Minimizing urinary toxicity in daily prostate stereotactic body radiotherapy with urethra dose constraints.
Kim, Hyun
Hanlon, Alexandra L.
Knotts, Walter E.
Noonan, Jodie A.
Raben, Adam
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer
Fiorino, C
Sanguineti, G
Cozzarini, C
Fellin, G
Foppiano, F
Menegotti, L
Piazzolla, A
Vavassori, V
Valdagni, R
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (04): : 953 - 962
[49] Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG)
Zagouri, F.
Peroukidis, S.
Tzatmis, K.
Kouloulias, V.
Bamias, A.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 93 (01) : 36 - 49
[50] Weekly On-Treatment Assessment of Genito-Urinary Symptoms Using a Modification of the AUA Symptom Index Worksheet for Patients Receiving Radiation for Prostate Cancer
Howell, D. D.
Schipper, M. J.
Hamstra, D. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S415 - S416

← 1 2 3 4 5 →